Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007 62:219–23. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al. Leukotriene E 4 in urine in patients with asthma and COPD: the effect of smoking habit. Gaki E, Papatheodorou G, Ischaki E, Grammenou V, Papa I, Loukides S. Methods to improve measurement of cysteinyl leukotrienes in exhaled breath condensate from subjects with asthma and healthy controls. Debley JS, Hallstrand TS, Monge T, Ohanian A, Redding GJ, Zimmerman J. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations.
Baraldi E, Carraro S, Alinovi R, Pesci A, Ghiro L, Bodini A, et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Csoma Z, Kharitonov SA, Balint B, Bush A, Wilson NM, Barnes PJ. Leukotrienes, antileukotrienes and asthma. New antimediator drug treatments: what use might they be? Eur Respir Rev 1998 54:184–9. New perspectives in monitoring lung inflammation: analysis of exhaled breath condensate. J Chromatogr B Analyt Technol Biomed Life Sci 2009 877:1272–80. LC/MS/MS analysis of leukotriene B 4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. Cysteinyl leukotriene receptors, old and new implications for asthma. Inflammatory mediators in blood and urine. Leukotriene modifiers for asthma treatment. Anti-inflammatory mechanisms of leukotriene modulators. The role of cigarette smoking on persistent airflow obstruction in asthma.
Challenges of treating asthma in people who smoke. Spears M, Cameron E, Chaudhuri R, Thomson NC.
Global strategy for asthma management and prevention. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.
In smoking asthmatics usage of agents that block the effects of LTD 4 can be beneficial however, new clinical studies are required.Ĭorresponding author: Sibel Doruk, MD, Faculty of Medicine, Department of Pulmonary Medicine, Gaziosmanpasa University, 60100 Tokat, Turkey Phone: +9500 (1310), Fax: +9179Īuthors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.ġ. LTE 4 concentrations in EBC were higher in asthmatics than healthy non-smokers. PFTs were different between Group I and Group III and there was a significant negative correlation between LTE 4 levels and forced expiratory volume in one second and forced vital capacity ratio in Group I.Ĭonclusions: LTD 4, but not LTE 4, concentrations in EBC were higher in asthmatic smokers than asthmatic non-smokers. LTE 4 levels were lower in Group III than other groups and similar in Group I and Group II. Results: LTD 4 levels were found to be higher in Group I than other groups and similar in Group II and Group III. LTD 4 and LTE 4 levels in EBC samples were analyzed by using ELISA. EBC samples were collected (EcoScreen, Jaeger, Hoechberg, Germany) and pulmonary function tests (PFTs) were performed in each case, and an asthma control questionnaire (ACQ) was completed by the asthmatics. As a control group (Group III), 29 healthy non-smokers were enrolled. Of them, 59 were asthmatics 30 of the 59 asthmatics were smokers (Group I) and the others were non-smokers (Group II). Methods: A total of 88 participants were included in the study. In this study, we aimed to determine leukotriene D 4 (LTD 4) and leukotriene E 4 (LTE 4) levels in exhaled breath condensate (EBC) in asthmatics and to evaluate the effect of smoking upon CysLTs levels and to speculate the importance of adding leukotriene receptor antagonists in smoking asthmatics. Background: Cysteinyl leukotrienes (CysLTs) are among important inflammatory mediators in asthma pathogenesis.
0 kommentar(er)
